Monday, Sep 21, 2020 | Last Update : 06:07 PM IST

180th Day Of Lockdown

Maharashtra118801585793332216 Andhra Pradesh6177765307115302 Tamil Nadu5364774812738751 Karnataka5113454048417922 Uttar Pradesh3362942632884771 Delhi2347011981034877 West Bengal2155801870614183 Telangana1713061397001033 Odisha167161133466722 Bihar164224149722855 Assam150349121610528 Kerala12221687341490 Gujarat119088999083271 Rajasthan109088906851293 Haryana103773816901069 Madhya Pradesh97906743981877 Punjab90032658182646 Chhatisgarh7777541111628 Jharkhand6710052807590 Jammu and Kashmir5971138521951 Uttarakhand3713924810460 Goa2678320844327 Puducherry2142816253431 Tripura2069612956222 Himachal Pradesh11190691997 Chandigarh92566062106 Manipur8430653951 Arunachal Pradesh6851496713 Nagaland5306407910 Meghalaya4356234232 Sikkim2119178923 Mizoram15069490
  Science   14 Apr 2020  Hydroxychloroquine study for coronavirus partly stopped as patients develop heart complications

Hydroxychloroquine study for coronavirus partly stopped as patients develop heart complications

AP
Published : Apr 14, 2020, 2:13 pm IST
Updated : Apr 14, 2020, 2:13 pm IST

One-fourth of those assigned to get 600 milligrams twice a day for 10 days developed heart rhythm problems, and trends suggested more deaths

Hydroxychloroquine has long been known to have potentially serious side effects, including altering the heartbeat in a way that could lead to sudden death (Photo | AP)
 Hydroxychloroquine has long been known to have potentially serious side effects, including altering the heartbeat in a way that could lead to sudden death (Photo | AP)

Rio de Janeiro: Scientists in Brazil have stopped part of a study of a malaria drug touted as a possible coronavirus treatment after heart rhythm problems developed in one-quarter of people given the higher of two doses being tested.

Chloroquine and a newer, similar drug called hydroxychloroquine, have been pushed by President Donald Trump after some very small, early tests suggested the drugs might curb the virus from entering cells. But the drugs have long been known to have potentially serious side effects, including altering the heartbeat in a way that could lead to sudden death.

 

The Brazilian study, in the Amazonian city of Manaus, had planned to enroll 440 severely ill COVID-19 patients to test two doses of chloroquine, but researchers reported results after only 81 had been treated.

One-fourth of those assigned to get 600 milligrams twice a day for 10 days developed heart rhythm problems, and trends suggested more deaths were occurring in that group, so scientists stopped that part of the study.

The other group was given 450 milligrams twice a day on the first day then once a day for four more days. That is closer to what's being tried in some other studies including some in the United States. It's too soon to know whether that will prove safe or effective; the Brazil study had no comparison group that was getting no treatment.

 

Only one participant in the Brazil study had no signs of the virus in throat swabs after treatment, researchers noted.

The results from the Brazil study were posted on a research website and have not yet been reviewed by other scientists.

Complicating matters is that all patients in the study also received two antibiotics, ceftriaxone and azithromycin. The latter also can have side effects on the heart. Trump has touted the hydroxychloroquine-azithromycin combination.

Brazil's President Jair Bolsonaro has repeatedly touted the benefits of chloroquine and azithromycin without evidence. He said at one point he heard reports of 100% effectiveness when administered in the correct dosages, zeroed tariffs for import of the drugs, and late last month announced military labs were ramping up their chloroquine production.

 

Tags: coronavirus (covid-19), hydroxychloroquine, anti-malaria drug, heart problems, coronavirus drug trial